After Hours
$
110.21
Change
-0.31 -0.28%
Volume
Volume 99,468
Jan 15, 2021, 7:59 p.m.
Quotes are delayed by 20 min
Previous close
$ 111.63
$ 110.52
Change
-1.11 -0.99%
Day low
Day high
$109.48
$111.56

52 week low
52 week high
$62.55
$113.41

Market cap
$195.12B
Average volume
8.13M
P/E ratio
23.37
Rev. per Employee
$1.11M
EPS
4.73
Dividend
1.30
Div yield
4.71%
Ex dividend date
1/14/21
MarketWatch News on ABBV
-
Global Dividends Will Rise 7% in 2021, IHS Markit Says, but U.S. Payouts Seen Falling
- Lawrence C. Strauss
-
The Case for AbbVie as a Top Biopharma Stock in 2021
- Josh Nathan-Kazis
-
Why Gilead Retreated From Arthritis-Drug Partnership
- Bill Alpert
-
Why Gilead Retreated From Arthritis-Drug Partnership
- Bill Alpert
-
Abbvie’s Plan to Make Up for Lost Humira Sales
- Bill Alpert
-
Nike, FedEx, Lennar, Eli Lilly, and Other Stocks to Watch This Week
- Nicholas Jasinski
-
AstraZeneca to Buy Alexion Pharmaceuticals for $39 Billion
- Luisa Beltran
-
BioNTech SE ADR stock falls Friday, underperforms market
- MarketWatch Automation
-
Moderna Inc. stock outperforms market on strong trading day
- MarketWatch Automation
-
AstraZeneca PLC ADR stock rises Friday, outperforms market
- MarketWatch Automation
-
AstraZeneca PLC ADR stock outperforms competitors despite losses on the day
- MarketWatch Automation
-
BioNTech SE ADR stock outperforms market on strong trading day
- MarketWatch Automation
-
Moderna Inc. stock falls Thursday, underperforms market
- MarketWatch Automation
-
AstraZeneca PLC ADR stock falls Wednesday, still outperforms market
- MarketWatch Automation
-
BioNTech SE ADR stock underperforms Wednesday when compared to competitors
- MarketWatch Automation
-
Moderna Inc. stock underperforms Wednesday when compared to competitors
- MarketWatch Automation
-
BioNTech SE ADR stock rises Tuesday, outperforms market
- MarketWatch Automation
-
Moderna Inc. stock outperforms market on strong trading day
- MarketWatch Automation
- Loading more headlines...
Analyst Ratings
-
What Analysts Recommend for Merck in March 2018
- MarketRealist.com
-
5 Biggest Price Target Changes For Friday
- Benzinga.com
Other News on ABBV
-
A Safe ETF to Buy That's Risen 22% in 12 Months
- Baystreet.ca
-
AbbVie: Undervalued Dividend Aristocrat Offering A 4.77% Yield
- Seeking Alpha
-
7 Pharmaceutical Stocks With Exciting Plans for 2021
- InvestorPlace.com
-
2021 JPMorgan Healthcare Conference Presentation
- Seeking Alpha
-
Evolus is up 6% after AbbVie-Cypris Medical deal
- Seeking Alpha
-
Nicholas Ward's Dividend Growth Portfolio: 2020 Review
- Seeking Alpha
- Loading more headlines...
Earnings Announcement
Press Releases on ABBV
-
A Safe ETF to Buy That's Risen 22% in 12 Months
- Baystreet.ca
- Loading more headlines...
Rates »
National averages from Bankrate.com
National averages from Bankrate.com
National averages from Bankrate.com